Format

Send to

Choose Destination
Toxicol Sci. 2018 Mar 1;162(1):36-42. doi: 10.1093/toxsci/kfx233.

Metabolic Syndrome and Associated Diseases: From the Bench to the Clinic.

Author information

1
Regulatory Activities, National Center for Toxicological Research, Food and Drug Administration, Silver Spring, Maryland 20993.
2
Division of Gastroenterology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina 27710.
3
The Warren Alpert Medical School of Brown University; Pediatric Endocrinology Rhode Island Hospital Providence, Rhode Island 02903.
4
Department of Microbiology and Immunology, Cornell University College of Veterinary Medicine, Ithaca, New York 14853.
5
Drug Safety Research and Development, Pfizer, Groton, Connecticut 06340.
6
Department of Environmental Toxicology, University of California at Davis, Davis, California 95616.
7
Kerk School of Medicine, University of Southern California, Los Angeles, California 90027 and Jean-Pierre Aubert Research Center, Jean-Pierre Aubert Research Center, Lille, France.
8
Division of Systems Biology, National Center for Toxicological Research, Food and Drug Administration, Jefferson, Arkansas 72079.
9
Hastings Toxicology Consulting LLC, Mount Airy, Maryland 21771.
10
Division of Extramural Research, National Institute of Environmental Health Sciences, Durham, North Carolina 27709.
11
Experimental Pathology, Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut 06877.
12
Burleson Research Technologies Inc, Morrisville, North Carolina 27560.

Abstract

Metabolic Syndrome and Associated Diseases: From the Bench to the Clinic, a Society of Toxicology Contemporary Concepts in Toxicology (CCT) workshop was held on March 11, 2017. The meeting was convened to raise awareness of metabolic syndrome and its associated diseases and serve as a melting pot with scientists of multiple disciplines (eg, toxicologists, clinicians, regulators) so as to spur research and understanding of this condition. The criteria for metabolic syndrome include obesity, dyslipidemia (low high-density lipoprotein and/or elevated triglycerides), elevated blood pressure, and alterations in glucose metabolism. It can lead to a greater potential of type 2 diabetes, lipid disorders, cardiovascular disease, hepatic steatosis, and other circulatory disorders. Although there are no approved drugs specifically for this syndrome, many drugs target diseases associated with this syndrome thus potentially increasing the likelihood of drug-drug interactions. There is currently significant research focusing on understanding the key pathways that control metabolism, which would be likely targets of risk factors (eg, exposure to xenobiotics, genetics) and lifestyle factors (eg, microbiome, nutrition, and exercise) that contribute to metabolic syndrome. Understanding these pathways could also lead to the development of pharmaceutical interventions. As individuals with metabolic syndrome have signs similar to that of toxic responses (eg, oxidative stress and inflammation) and organ dysfunction, these alterations should be taken into account in drug development. With the increasing frequency of metabolic syndrome in the general population, the idea of a "normal" individual may need to be redefined. This paper reports on the substance and outcomes of this workshop.

PMID:
29106690
PMCID:
PMC6256950
DOI:
10.1093/toxsci/kfx233
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center